Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.

Phase 3 Completed 411 enrolled Takeda

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with simvastatin on cholesterol levels in subjects with primary dyslipidemia

Timeline

Start: 2005-10
Primary completion: 2007-03
Completion: 2007-03

Publications

Results Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 May 10;123(18):1974-85. doi: 10.1161/CIRCULATIONAHA.110.975284. Epub 2011 Apr 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lapaquistat acetate	Small molecule	50 mg	Oral
Subject	Lapaquistat acetate	Small molecule	100 mg	Oral
Subject	Simvastatin	Small molecule	20 mg	Oral
Subject	Simvastatin	Small molecule	40 mg	Oral

Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.

Summary

Timeline

Publications

Drugs

Indications